{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:27:35Z","timestamp":1761488855772},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/bmt.2012.10","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T12:27:19Z","timestamp":1329136039000},"page":"1318-1320","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma"],"prefix":"10.1038","volume":"47","author":[{"given":"N","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B N","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"BFbmt201210_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.beha.2011.03.008","volume":"24","author":"IF Khouri","year":"2011","unstructured":"Khouri IF . Allogeneic stem cell transplantation in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 271\u2013277.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt201210_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236\u2013245.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201210_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","volume":"17","author":"MR Tomblyn","year":"2011","unstructured":"Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011; 17: 1051\u20131057.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201210_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ajh.22099","volume":"86","author":"A Freedman","year":"2011","unstructured":"Freedman A . Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011; 86: 768\u2013775.","journal-title":"Am J Hematol"},{"key":"BFbmt201210_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","volume":"20","author":"AJ Barrett","year":"2006","unstructured":"Barrett AJ, Savani BN . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661\u20131672.","journal-title":"Leukemia"},{"key":"BFbmt201210_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2141.2006.06308.x","volume":"135","author":"H de Lavallade","year":"2006","unstructured":"de Lavallade H, Mohty M, El-Cheikh J, Cassier PA, Faucher C, F\u00fcrst S et al. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006; 135: 408\u2013410.","journal-title":"Br J Haematol"},{"key":"BFbmt201210_CR7","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530\u20135536.","journal-title":"Blood"},{"key":"BFbmt201210_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/bmt.2010.225","volume":"46","author":"M Shafey","year":"2011","unstructured":"Shafey M, Lupichuk SM, Do T, Owen C, Stewart DA . Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant 2011; 46: 962\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201210_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/bmt.2009.214","volume":"44","author":"CO Freytes","year":"2009","unstructured":"Freytes CO, Lazarus HM . Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? Bone Marrow Transplant 2009; 44: 559\u2013569.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201210_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2011.05.002","volume":"17","author":"N Reddy","year":"2011","unstructured":"Reddy N, Savani BN . Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant 2011; 17: 1265\u20131272.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201210_CR11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","volume":"17","author":"T Shea","year":"2011","unstructured":"Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395\u20131403.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201210_CR12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","volume":"95","author":"JL Pinana","year":"2010","unstructured":"Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, D\u00edez-Mart\u00edn JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176\u20131182.","journal-title":"Haematologica"},{"key":"BFbmt201210_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/bmt.2010.339","volume":"46","author":"KE Abou-Nassar","year":"2011","unstructured":"Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 2011; 46: 1503\u20131509.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201210_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/bmt.2008.323","volume":"43","author":"R Buhmann","year":"2009","unstructured":"Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009; 43: 383\u2013397.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201210_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/bmt.2008.382","volume":"43","author":"LK Hicks","year":"2009","unstructured":"Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701\u2013708.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201210","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:09:10Z","timestamp":1648048150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFbmt201210"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.10","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]},"assertion":[{"value":"4 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}